Hyderabad: Dr Reddy’s Laboratories on Monday announced the commercial launch of the anti-COVID oral drug 2-deoxy-D-Glucose (2-DG).
The lab will supply it to major government as well as private hospitals in the country.
The anti-Covid drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s.
“Anti-Covid drug 2-DG manufactured by Dr Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidised rate offered to government institutions,” said a press statement.
“In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India,” the release added.
Emergency use approval for the anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.
The drug (2-DG) can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.
